Background {#Sec1}
==========

Active smoking has been recognized as a critical lifestyle factor for cardiovascular, respiratory, and neoplastic diseases and contributes to the leading causes of preventable morbidity and mortality \[[@CR1], [@CR2]\]. DNA methylation, one of the main forms of epigenetic modification, is involved in the pathways of smoking and smoking-induced diseases \[[@CR3], [@CR4]\]. Previous epigenome-wide association studies (EWASs) based on whole blood samples have successfully discovered an increasing number of tobacco smoking-related CpG sites in various genes, such as *AHRR* and *F2RL3* \[[@CR5]--[@CR7]\]. These DNA methylation patterns have been shown to be useful as quantitative biomarkers to reflect both current and lifetime smoking exposure and to enhance the prediction of smoking-related risks \[[@CR8]--[@CR11]\].

DNA methylation of particular genomic loci might be influenced by neighboring genetic sequence variants \[[@CR12]\]. The single nucleotide polymorphisms (SNPs) that are associated with methylation levels of CpG sites are known as methylation quantitative trait loci (mQTLs) \[[@CR13]\]. This genetic effect has been determined across different tissues \[[@CR13]--[@CR16]\] and has been highlighted in several diseases, including neurological disorders, arthritis, and cancer \[[@CR17]--[@CR21]\]. Recently, the mQTLs have been further reported to play a modifying role in the associations between DNA methylation levels at specific CpG sites and environmental exposures. For instance, Zhang et al. identified 238 mQTLs that were associated with 65 alcohol dependence-related CpG sites in African Americans and 305 mQTLs for 44 unique CpG sites in European Americans \[[@CR22]\]. In 2016, Gonseth et al. found out that three of the strongest maternal smoking-related CpG sites in newborns were significantly associated with SNPs located in the vicinity of each gene \[[@CR23]\]. Thus, these hereditary traits provide a possible mechanism by which methylation patterns could be different under environmental exposures, if the distribution of risk alleles differs between the exposed and the unexposed. In addition, the linkages of epigenetic signatures to genotypes might also further provide more mechanistic evidence on the genetic and environmental risk factors for various forms of diseases \[[@CR24]\].

However, such genetic influences have not been well addressed or even overlooked by previous EWASs of active smoking exposure; to our knowledge, no study has so far investigated their contributions to the methylation intensities of active smoking-related CpG sites and smoking-related health outcomes in the general population. Therefore, we conducted a comprehensive analysis in a large population-based study of older adults in Germany with the aim of exploring the hitherto unknown association between active smoking-related DNA methylation and individual genetic variations. In particular, we aimed to identify the mQTLs within ± 50 kb from each of 151 previously reported active smoking-related CpG sites in whole blood samples \[[@CR25]\] and to assess their relationships with active smoking exposure and all-cause mortality.

Results {#Sec2}
=======

Participant characteristics {#Sec3}
---------------------------

Characteristics of the study population in the discovery and the validation panel with respect to smoking behaviors and lifestyle factors are summarized in Table [1](#Tab1){ref-type="table"}. The average age of the participants of both subsets at the baseline was about 61 years. About half of the participants in each subset were ever smokers (current or former smokers), and around 18% still smoked at the time of recruitment. Female participants included a larger proportion of never smokers than males (discovery set, 67.9 vs. 28.6%; validation set, 63.3 vs. 21.4%). Average cumulative smoking exposure (pack-years) of current smokers was considerably higher than that of former smokers in both subsets (discovery set, 34.6 vs. 22.0; validation set, 33.1 vs. 19.4). Average time after smoking cessation (years) of former smokers in both subsets was also similar, approximately 17 years. The majority of participants in both subsets of the study population were overweight or obese, reported no or only low physical activity, and no or low amounts of alcohol drinking. During a median follow-up time of about 12 years (discovery set, 12.6 years; validation set, 12.2 years), 94 participants died in the discovery set (CVD = 30, cancer = 46, other diseases = 18) and 49 died in the validation set (CVD = 17, cancer = 21, other diseases = 11).Table 1Study population characteristics in discovery and validation panels (mean values (SD) for continuous variables and *n* (%) for categorical variables)CharacteristicsDiscovery panelValidation panel*p* value*N*581368Age (years)61.0 (6.3)61.1 (6.4)0.809Sex (male)241 (41.5%)117 (31.8%)\< 0.001Smoking status0.864 Current smoker108 (18.6%)65 (17.7%) Former smoker173 (29.8%)119 (32.3%) Never smoker300 (51.6%)184 (50.0%)Pack-years of smoking^a^ Current smokers34.6 (18.2)33.1 (18.2)0.250 Former smokers22.0 (17.5)19.4 (15.5)0.033Smoking cessation time (years)^b^16.5 (11.3)17.2 (10.2)0.742Body mass index^c^0.248 Underweight or normal weight (\< 25.0)143 (24.7%)116 (31.5%) Overweight (25.0--\< 30.0)290 (50.2%)151 (41.0%)vObese (≥ 30.0)145 (25.1%)101 (27.5%)Alcohol consumption^d^0.509 Abstainer194 (36.3%)128 (38.0%) Low301 (56.4%)188 (55.8%) Intermediate30 (5.6%)17 (5.0%) High9 (1.7%)4 (1.2%)Physical activity^e^0.058 Inactive109 (18.8%)82 (22.3%) Low245 (42.2%)176 (47.8%) Medium or high227 (39.0%)110 (29.9%)Prevalence of CVD at baseline^f^0.621 Prevalent86 (14.8%)58 (15.8%)Prevalence of diabetes at baseline^g^0.617 Prevalent86 (14.9%)60 (16.6%)Prevalence of cancer at baseline Prevalent33 (5.7%)22 (6.0%)0.744^a^For subgroups of former and current smokers; data missing for 38 and 24 participants, respectively, in discovery and validation panels; a pack-year was defined as having smoked 20 cigarettes per day for 1 year^b^Former smokers only, data missing for 5 and 2 participants, respectively, in discovery and validation panels; cessation time equals age at recruitment minus age at cessation^c^Data missing for 3 participants in discovery panel^d^Data missing for 47 and 31 participants, respectively, in discovery and validation panels. Categories defined as follows: abstainer, low \[women, 0--\< 20 g/d; men, 0--\< 40 g/d\], intermediate \[20--\< 40 g/d and 40--\< 60 g/d, respectively\], high \[≥ 40 g/d and ≥ 60 g/d, respectively\]^e^Categories defined as follows: inactive \[\< 1 h of physical activity/week\], medium or high \[≥ 2 h of vigorous or ≥ 2 h of light physical activity/week\], low (other)^f^CVD cardiovascular disease. Data missing for 1 participant in discovery panel^g^Data missing for 5 and 7 participants, respectively, in discovery and validation panels

Identification of mQTLs for smoking-related CpG sites {#Sec4}
-----------------------------------------------------

For the 1396 SNP-CpG pairs consisting of 150 smoking-related CpG sites and 909 corresponding SNPs (Fig. [1](#Fig1){ref-type="fig"}), 380 pairs were significant at a FDR \< 0.05 in the discovery panel even after controlling for covariates (Additional file [1](#MOESM1){ref-type="media"}: Table S2; Additional file [2](#MOESM2){ref-type="media"}: Figure S1). These 380 pairs were then replicated in the validation panel by applying the fully adjusted mixed linear regression model. A subset of 246 pairs formed of 70 CpG sites and 192 SNPs reached the statistical significance level after FDR correction (FDR \< 0.05; Table [2](#Tab2){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Table S3, Additional file [1](#MOESM1){ref-type="media"}: Table S4; Fig. [2](#Fig2){ref-type="fig"}). Eventually, 192 SNPs were designated as the mQTLs of 70 CpG sites. The pair cg23576855/rs75509302 showed the strongest inter-relationship (FDR-corrected *p* value = 8.86 e − 103). Among the 70 CpG sites, five were highly smoking-related loci (reported ≥ 6 times; Table [3](#Tab3){ref-type="table"}), 14 were moderately smoking-related (4 or 5 times), and 51 were weakly smoking-related (2 or 3 times). These CpG sites with mQTLs were mainly located in the gene body (37/70), ten were located in transcription start sites (TSS1500) and 23 were in untranslated regions (UTR) or intergenetic regions (Additional file [1](#MOESM1){ref-type="media"}: Table S3). The largest number of mQTLs (*n* = 8) was found for locus cg06126421 within *6p21.33* (Table [3](#Tab3){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). The coefficients of mQTLs ranged from −0.54 to 0.15.Fig. 1Flowchart of selection of SNP-CpG pairs Table 2List of 246 significant SNP-CpG pairs (chromosomal and CpG sites positions were based on GRCh37/hg19)ChromosomeGeneCpG sitePositionNumber of SNP candidatesNumber of mQTLs1*AVPR1B*cg0906907215,482,754135*GFI1*cg0966241192,946,132102cg0993538892,947,588102cg1039978992,945,66896cg1287635692,946,825102cg1814673792,946,701102cg1831697492,947,035102*GNG12*cg2518990468,299,49352*NOS1AP*cg11231349162,050,65742*TMEM51*cg2191388615,485,346149*unassigned*cg03547355227,003,06182*unassigned*cg125478079,473,75191*unassigned*cg2139316312,217,63082*unassigned*cg2676424468,299,511332*2q37.1*cg05951221233,284,40251cg03329539233,283,32952*ALPP*cg23667432233,244,43952*NFE2L2*cg26271591178,125,95686*SNED1*cg26718213241,976,08194*unassigned*cg27241845233,250,371523*GPX1*cg1864223449,394,6231055*AHRR*cg03604011400,201155cg03991871368,44891cg11902777368,84394cg12806681368,39592cg14817490392,920154cg17287155393,347151cg23576855373,30097cg23916896368,805946*6p21.33*cg0612642130,720,081168*CDKN1A*cg1547457936,645,813228*IER3*cg1534208730,720,210162cg2485943330,720,204163*TIAM2*cg00931843155,442,99361*VARS*cg1761975531,760,629168*unassigned*cg1475335630,720,109827*C7orf40*cg0344094445,023,33051*CNTNAP2*cg11207515146,904,206147cg25949550145,814,306118*GNA12*cg197177732,847,5542222*HOXA7*cg0839619327,193,70971*LRRN3*cg11556164110,738,31655*MYO1G*cg1280306845,002,919101cg2213278845,002,487101*TNRC18*cg090222305,457,2262438*ZC3H3*cg26361535144,576,60481*unassigned*cg19589396103,937,3741529*unassigned*cg01692968108,005,3492210*ARID5B*cg2595313063,753,5506311*KCNQ1*cg071231822,722,391132cg269632772,722,408133cg017443312,722,358133*KCNQ1OT1*cg165566772,722,402132*PRSS23*cg1166001886,510,91592cg2377136686,510,99992*unassigned*cg1661123458,870,075101014*C14orf43*cg0173178374,211,78961cg1091952274,227,4415115*ANPEP*cg2316149290,357,203196*SEMA7A*cg0031041274,724,91913916*ITGAL*cg0909983030,485,48632*XYLT1*cg1679457917,562,4193117*LOC100130933*cg0725188773,641,81062*STXBP4*cg0746562753,167,4078419*CPAMD8*cg1515998717,003,890154*CRTC1*cg2397352418,873,223121*F2RL3*cg0363618317,000,586171*PPP1R15A*cg0370716849,379,12710421*ETS2*cg2311042240,182,0736322*NCF4*cg0253270037,257,40482Total590246 Fig. 2Manhattan plot of the results in validation panel. Red line, FDR-corrected *p* value = 0.05 Table 3Five frequently reported (≥ 6) CpG sites and corresponding mQTLsCpG siteFrequency^a^GeneChrSNPSNP position^b^Minor alleleDistance (bp)^c^FDR^d^MAF^e^cg0363618312*F2RL3*19rs222735717,003,553A29670.0480.125cg059512218*2q37.1*2rs79005130,718,035A− 18666.2 e − 40.226cg061264217*6p21.33*6rs253532430,727,983C− 20461.8 e − 90.3rs309533930,728,290G79022.6 e − 40.252rs313103630,728,360A82092.6 e − 40.253rs309412230,737,552G82793.2 e − 30.206rs1321791430,739,657A17,4712.4 e − 210.157rs691157130,753,639T19,5760.0070.16rs471336130,756,066A33,5581.3 e − 210.159rs1320176930,718,035A35,9856.9 e − 70.326cg033295396*2q37.1*2rs790051233,282,536A− 7930.0310.226rs34547337233,300,755T17,4261.5 e − 50.314cg148174906*AHRR*5rs75509302365,653C− 27,2670.0020.144rs11746079410,980C18,0601.5 e − 30.154rs72717419431,996T39,0760.0210.207rs2672725434,981G42,0610.0420.117^a^The reported times of CpG in previous studies (based on systematic review \[[@CR25]\])^b^Positions of CpG sites and SNPs were based on GRCh37/hg19^c^The distance between SNP and CpG (SNP position--CpG position)^d^The FDR-corrected *p* values of SNPs in fully adjusted mixed linear regression models, which controlled for age (years), sex, smoking status, random batch effect of methylation measurement, leukocyte distribution (Houseman algorithm), alcohol consumption (abstainer/low/intermediate/high), body mass index (BMI, underweight or normal weight/overweight/obese), physical activity (inactive/low/medium or high), prevalence of cardiovascular diseases (yes/no), prevalence of diabetes (yes/no), and prevalence of cancer (yes/no)*eMAF* minor allele frequency Fig. 3Locations of cg06126421 and eight mQTLs (carrier/non-carrier) (**a**) and distributions of methylation levels based on smoking status (**b**) in validation panel. Red line, FDR-corrected *p* value = 0.05; red dot, mQTLs; yellow triangle, cg06126421; blue bar, non-carriers of minor allele; red bar, carriers of minor allele

The 192 mQTLs were mainly mapped on chromosomes 1 (16%), 6 (10%), and 7 (25%). Three SNPs were the most frequently identified mQTLs, rs75509392 (MAF = 0.144) for eight CpG sites within *AHRR*, rs79050605 (MAF = 0.202), and rs34835481 (MAF = 0.210) for five and six CpG sites located in *GFI1*, respectively (Table [4](#Tab4){ref-type="table"}). We assessed the effects of the mQTLs on the DNA methylation changes as the absolute values of the coefficient changes of smoking status between the models without and with adjusting for corresponding mQTLs (carrier/non-carrier) among the 246 SNP-CpG pairs (Additional file [1](#MOESM1){ref-type="media"}: Table S5). Part of the mQTLs had opposite effects on different CpG sites (Additional file [1](#MOESM1){ref-type="media"}: Table S5, Additional file [3](#MOESM3){ref-type="media"}: Figure S2). For example, the minor allele of the SNP rs75509302 attenuated the association of smoking exposure with the methylation of cg11902777 by 5.2% (Additional file [1](#MOESM1){ref-type="media"}: Table S5, Additional file [3](#MOESM3){ref-type="media"}: Figure S2). In contrast, this variant strengthened the demethylation of cg17287155 in response to different smoking behaviors by 2.44%.Table 4Three most frequently identified mQTLs and corresponding CpG sitesSNPChrSNP position^a^Minor alleleMAF^b^CpGDistance (bp)^c^FDR^d^rs755093025365,653C0.144cg23576855− 76473.4 e − 100cg11902777− 31901.4 e − 7cg17287155− 27,6947.8 e − 5cg03991871− 27951.0 e − 4cg12806681− 27421.2 e − 4cg23916896− 31529.5 e − 4cg03604011− 34,5481.1 e − 3cg14817490− 27,2672.1 e − 3rs34835481192,991,624T0.210cg1039978945,9562.2 e − 5cg1287635644,7991.3 e − 3cg0966241145,4921.9 e − 3cg1814673744,9232.0 e − 3cg1831697444,5893.0 e − 3cg0993538844,0360.016rs79050605192,925,962G0.202cg12876356− 20,8633.7 e − 4cg18146737− 20,7391.1 e − 3cg18316974− 21,0731.7 e − 3cg09662411− 20,1701.9 e − 3cg09935388− 21,6262.2 e − 3^a^SNPs positions were based on GRCh37/hg19^b^MAF minor allele frequency^c^The distance between SNP and CpG (SNP position--CpG position)^d^The FDR-corrected *p* values of SNPs in fully adjusted mixed linear regression models, which controlled for age (years), sex, smoking status, random batch effect of methylation measurement, leukocyte distribution (Houseman algorithm), alcohol consumption (abstainer/low/intermediate/high), body mass index (BMI, underweight or normal weight/overweight/obese), physical activity (inactive/low/medium or high), prevalence of cardiovascular diseases (yes/no), prevalence of diabetes (yes/no), and prevalence of cancer (yes/no)

Genetic contributions of mQTLs to the DNA methylation changes {#Sec5}
-------------------------------------------------------------

As shown in Additional file [1](#MOESM1){ref-type="media"}: Table S5, the associations between smoking exposure and DNA methylation were changed by between 0.01 and 18.96% by the mQTLs and were categorized by the distances between genetic variants and CpG sites and the reported frequencies of CpG sites. We observed that the closest SNPs (distance \< 10 kb) had a slightly lower impact on DNA methylation levels than the mQTLs located ≥ 10 kb (Fig. [4](#Fig4){ref-type="fig"}a). Compared with the highly smoking-related CpG sites, the mQTLs affect the methylation levels of weakly smoking-related CpG sites the most, and the changes of moderately smoking-related CpG sites stayed in the intermediate position (Fig. [4](#Fig4){ref-type="fig"}b, *F* = 4.91, *p* value = 0.008). Additionally, potential gene-environment interactions of the 192 mQTLs with smoking behaviors (current/never smoking) were assessed. Only for rs75509302, a significant interaction with smoking was observed regarding the methylation levels of cg23576855 (Tables [5](#Tab5){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Table S6).Fig. 4Percentage changes contributed by mQTLs to smoking-related DNA methylation changes based on SNP-CpG distance (**a**) and reported frequencies of CpG sites (**b**) Table 5Impact of rs75509302-smoking interaction on the methylation level of cg23576855^a^GeneCpG siteSNPSNP-smoking interaction^b^Smoking status^d^Genotype^c^CoefficientSE*p* valueCoefficientSE*p* value*AHRR*cg23576855rs75509302TTRef−0.1827.1 e − 33.8 e − 95CT0.1280.0131.1 e − 20CC0.2680.0332.5 e − 15^a^Model is fully adjusted for age, sex, BMI, smoking status (current and never smoking only), alcohol consumption, physical activity, prevalence of CVD, diabetes and cancer at baseline. The methylation levels of CpG sites were responses, the SNPs and SNP-smoking interactions were predictors;^b^The never smoking \* genotype groups and current smoking \* TT group were used as references;^c^The group of interaction between current smoking and listed genotype;^d^Never smoking was used as reference

Associations of mQTLs with active smoking exposure and all-cause mortality {#Sec6}
--------------------------------------------------------------------------

Finally, we tested the associations of the 192 mQTLs (carrier/non-carrier) with different measurements of smoking exposure \[ever smoking (current and former smoking) vs. never smoking, current smoking vs. never smoking, current smoking vs. former smoking, cumulative smoking (pack-years), durations of smoking (years), and the age of smoking initiation\]. None of them was significantly associated with any smoking indicators after the correction of FDR (Additional file [1](#MOESM1){ref-type="media"}: Table S7). Similarly, the 192 SNPs were not significantly associated with all-cause mortality (death from CVD, cancer, and other chronic diseases) based on the results of the COX model (Additional file [1](#MOESM1){ref-type="media"}: Table S8).

Discussion {#Sec7}
==========

We conducted the first association study of 150 active smoking-related CpG sites and their corresponding SNPs located in the ± 50 kb region utilizing the genomic and epigenomic data of 949 participants from the ESTHER study. We found the DNA methylation levels of 70 CpG sites to be influenced by 192 proximal SNPs. These 192 mQTLs modified the DNA methylation changes in response to active smoking exposure, especially for the weakly/moderately active smoking-related CpG sites, but we did not observe any direct associations with active smoking exposure or all-cause mortality.

The mQTLs are presented in the vicinity of active smoking-related CpG sites. Locus cg06126421 (*6p21.33*) is one of the pronounced smoking-related CpG sites with eight mQTLs. Four of the SNPs could impair the hypomethylation of cg06126421, while others could accelerate this process. All of these mQTLs were located in a genomic region relating to inflammation and/or immune-related (malignant) diseases, such as allergies \[[@CR26]\], multiple myeloma \[[@CR27]\], diffuse large B cell lymphoma \[[@CR28]\], and lung cancer \[[@CR29]\]. We also identified a mQTL rs2227357 which could slightly promote the demethylation of cg03636183 (*F2RL3*), but no mQTLs were discovered near other well-established smoking-related loci, like cg05575921 (*AHRR*) or cg19859270 (*GPR15*). However, eight CpG sites within the *AHRR* region were found to be modified by mQTLs. Among them, cg23576855 manifested the strongest connection with rs75509302 and was also the only hit which could be affected by the interaction between smoking status and corresponding mQTL. This phenomenon might be highly contributed by the genetic feature of this locus, which is also a CG → CA SNP annotated as rs6869832 \[[@CR5], [@CR30]\], and shares a very high LD with rs75509302 in this study (R^2^ = 0.94). Nevertheless, to our knowledge, the biological functions for most of the identified mQTLs in our study are not fully understood yet and need to be explored in further research.

The mQTLs may help to distinguish between the genetic and environmental effects on epigenome disparities. Researchers usually observed several outliers out of the predictive range of epigenetic signatures in EWASs \[[@CR6], [@CR7], [@CR9], [@CR31]\]. One of the most plausible explanations is measurement bias that may result from recall bias or intentional underreporting \[[@CR32]\]. Our finding provides another possibility that the deviations of DNA methylation levels might be caused by neighboring genetic variants. For highly smoking-related CpG sites, active smoking is still the main driver of DNA methylation changes. For instance, the SNP rs2227357 only contributed to about 0.01% of the changes of the methylation level of cg03636183 (*F2RL3*), and the SNP rs790051 altered only 0.37% of the methylation level of cg05951221 (*2q37.1*). However, the mQTLs affected the methylation levels of less robustly smoking-related loci much more. For instance, the SNPs rs78131 and rs2741302 explained nearly 19% of the changes of cg26963277 (*KCNQ1*) and cg27241845, respectively. While additional external validation studies certainly are needed, we speculate that this strong diversity of results might be a result of undetermined biological interactions between the SNP and CpG sites.

Smoking-related CpG sites have been recognized as informative signatures of smoking exposure and smoking-related health outcomes \[[@CR3], [@CR4]\]. Part of these 70 CpG sites with mQTLs have been reported to be highly associated with long-term smoking exposure \[cg03636183 (*F2RL3*) and cg06126421 (*6p21.33*)\] \[[@CR9], [@CR10]\], aging-related health outcomes, such as telomere length (cg21393163) \[[@CR33]\] and the development of frailty \[cg14753356, cg19589396, cg23667432 (*ALPP*) and cg25189904 (*GNG12*)\] \[[@CR34]\], and were even employed to construct a comprehensive index to predict smoking impact in buccal cells \[[@CR35]\]. Together with previous studies \[[@CR8], [@CR23]\], we suggest that future investigations utilizing smoking-related CpG sites might need to take the genotypes, especially the mQTLs of less robustly smoking-related loci, into consideration to account for their potential impact on DNA methylation levels.

Beyond the SNP-CpG associations, null associations of 192 mQTLs with active smoking and all-cause mortality additionally imply that these novel genetic variants might be independently associated with the DNA methylation changes and might not be involved in the pathophysiological development of smoking-related health outcomes. Therefore, these mQTLs might have the potential to be used in the causal inference tests between the CpG sites and smoking-related health outcomes as instrumental variables (Mendelian Randomization, MR) \[[@CR36]\]. Recently, researchers have suggested a two-stage MR test to establish the causal role of epigenetic processes in pathways of diseases \[[@CR37]\]. Larger population-based investigations with longitudinal design and repeated measurements of smoking exposure and epigenome data are warranted to evaluate these potential instrumental variables and obtain further insights into the plausibility of suggested causal effects of DNA methylation in the development of smoking-related diseases.

Major strengths of the present study include comprehensive information on a broad range of covariates in a population-based cohort and validation in an independent subgroup. Some limitations still have to be acknowledged in the interpretation of study results. First, smoking-related shifts in leukocyte distribution might affect the associations of DNA methylation in whole blood samples with active smoking \[[@CR38]\]. Hence, we adjusted for leukocyte distribution by the Houseman algorithm to restrict potential confounding from differential blood counts to the greatest possible extent \[[@CR39]\]. Further studies are also needed to evaluate to what extent our results can be generalized to middle-aged individuals or non-Caucasians, as the ESTHER study was conducted in the older (aged 50--75 years), almost exclusively Caucasian population in southern Germany during a routine screening program. In addition, our study had limited power for detecting direct associations of mQTLs with smoking exposure and all-cause mortality due to limited numbers of cases. Finally, we only measured a relatively small window of genetic regions (± 50 kb) in whole blood DNA due to the consideration of controlling for the pleiotropic effect or reverse causations from unknown genetic or epigenetic factors and the limited coverage of OncoArray \[[@CR40]\], more mQTLs (*cis*- or *trans*-) for smoking-related CpG sites need to be established by expanding the search window. Since DNA methylation is highly tissue-specific, larger cohorts with various human tissues are also needed for more comprehensive evaluation of the whole landscape of genetic impact on the epigenome.

Conclusions {#Sec8}
===========

In conclusion, this study identified 192 mQTLs for 70 smoking-related CpG sites. These variants might theoretically reflect inherited differences in epigenetic states of people and their susceptibilities to smoking-related health outcomes. Incorporation of mQTLs might enhance the epigenetic-based assessments of smoking or smoking-related health outcomes by accounting for potential confounding from genetic background. Our results need to be further validated and confirmed in additional studies with larger number of participants and more detailed assessment of genomic and epigenomic data, including the CpG sites that have not previously been replicated. Along with previous investigations on the epigenetic changes related to other environmental exposures or lifestyle factors, our study adds evidence for the complex interplays among genetic traits, epigenetic signatures, and environmental factors.

Methods {#Sec9}
=======

Study design and population {#Sec10}
---------------------------

Study subjects were selected from the ESTHER study, an ongoing statewide population-based cohort study conducted in Saarland, a state located in southwestern Germany. Details of the study design have been reported previously \[[@CR41]\]. Briefly, 9949 older adults (aged 50--75 years) were enrolled by their general practitioners during a routine health check-up between July 2000 and December 2002 and followed up thereafter. The current cross-sectional analysis is based on data and biospecimen collected at baseline. Two independent subgroups were selected as the discovery and the validation panel for DNA methylation analyses as previously described \[[@CR33]\]. Briefly, the discovery panel included 581 participants recruited consecutively at the start of the ESTHER study between July and October 2000. The validation panel included 368 participants randomly selected from the participants recruited between October 2000 and March 2001. The study was approved by the ethics committees of the University of Heidelberg and the state medical board of Saarland, Germany. Written informed consent was obtained from all participants.

Data collection {#Sec11}
---------------

Information on socio-demographic characteristics, lifestyle factors, and health status at baseline was obtained by standardized self-administered questionnaires. In particular, detailed information on lifetime smoking history was obtained, including current smoking status and intensity, age at initiation, and smoking intensities at various ages, as well as the age of quitting smoking for former smokers \[[@CR42]\]. Additional information on body mass index (BMI) was extracted from a standardized form filled by the general practitioners during the health check-ups. Prevalent cardiovascular disease (CVD) at baseline was defined by either physician-reported coronary heart disease or a self-reported history of a major cardiovascular event, such as myocardial infarction, stroke, pulmonary embolism, or revascularization of coronary arteries. Prevalent diabetes was defined by physician diagnosis or the use of glucose-lowering drugs. Prevalent cancer \[ICD-10 C00-C99 except non-melanoma skin cancer (C44)\] was determined by self-report or record linkage with data from the Saarland Cancer Registry (<http://www.krebsregister.saarland.de/ziele/ziel1.html>; in German). Deaths during the follow-up (between 2000 and end of 2014) were identified by record linkage with population registries in Saarland. Participants migrated out of Saarland were censored at the date last known to be alive. Information about the major cause of death was obtained from death certificates provided by the local public health offices and was coded with ICD-10 codes.

DNA methylation data {#Sec12}
--------------------

Blood samples were taken during the health check-up and stored at −80 °C until further processing. DNA from whole blood samples was collected using a salting out procedure \[[@CR43]\]. DNA methylation profiles were extracted by the Illumina Human Methylation 450K BeadChip (Illumina, San Diego, CA, USA). As previously described \[[@CR44]\], samples were analyzed following the manufacturer's instruction at the Genomics and Proteomics Core Facility of the German Cancer Research Center, Heidelberg, Germany. Illumina's GenomeStudio® (version 2011.1; Illumina, Inc.) was employed to extract DNA methylation signals from the scanned arrays (Module version 1.9.0; Illumina, Inc.). The methylation level of a specific CpG site was quantified as a *β* value ranging from 0 (no methylation) to 1 (full methylation). According to the manufacturer's protocol, no background correction was done and data were normalized to internal controls provided by the manufacturer. All controls were checked for inconsistencies in each measured plate. Probes with a detection *p* value \> 0.05 were excluded from analysis. We utilized the Illumina normalization and preprocessing method implemented in Illumina's GenomeStudio®. We selected the profiles of 151 smoking-related loci which had been identified ≥ 2 times in previous smoking EWASs for the present analysis \[[@CR25]\].

Genotyping data {#Sec13}
---------------

Extracted DNA from blood cells was genotyped using the Illumina Infinium OncoArray BeadChip (Illumina, San Diego, CA, USA). General genotyping quality control assessment was as previously described \[[@CR45]\]. Genotypes for common variants across the genome were imputed using data from 1000 Genomes Project (phase 3, Oct. 2014) with IMPUTE2 v2.3.2 after pre-phasing with SHAPEIT software v2.12. We set thresholds for imputation quality to retain both potential common and rare variants for validation. Specifically, poorly imputed SNPs defined by an information metric *I* \< 0.70 were excluded. All genomic locations are given in NCBI Build 37/UCSC hg19 coordinates. All SNPs having a MAF \< 1% were excluded. After imputation, the SNP set consisted of 9,198,808 genotyped and imputed SNPs. PLINK v1.90 was then used to extract SNPs for the required regions of interest \[[@CR46]\]. As shown in Fig. [1](#Fig1){ref-type="fig"}, we first identified SNPs within 50 kb upstream and downstream from each of the 151 smoking-related CpG sites (470,582 SNP-CpG pairs), a window in which most SNPs with significant *cis* associations with CpG sites are located \[[@CR13]\]. The locus cg01208318 was excluded without any corresponding SNPs in this restricted region. For each of the remaining 150 CpG sites, we excluded any SNPs with ≥ 1% missing values (*n* = 44,931), deviating from the Hardy-Weinberg equilibrium (HWE exact test's *p* value \< 0.0001, *n* = 1), with a minor allele frequency ≤ 0.1 (*n* = 414,671) or with high linkage disequilibrium (LD, *R* ^2^ ≥ 0.5) (Additional file [1](#MOESM1){ref-type="media"}: Table S1). After the final quality control, 1396 SNP-CpG pairs with strongest SNPs remained for analysis, which were constituted of 150 CpG sites and 909 corresponding SNPs (Additional file [1](#MOESM1){ref-type="media"}: Table S2).

Statistical analyses {#Sec14}
--------------------

First, major socio-demographic characteristics, lifestyle factors, smoking behavior, and prevalence of major chronic diseases in both the discovery and the validation panel were summarized by descriptive statistics.

We then evaluated the associations between the methylation intensities of the 150 CpG sites and corresponding SNPs to identify mQTLs as follows. For all SNP-CpG pairs, we used a mixed linear regression model with methylation batch as a random effect in which the methylation level of CpG site was the outcome and each regional SNP was the predictor (categorical variable, coded into 0, 1, and 2 based on the numbers of the minor allele). The model was fully adjusted for the following covariates that have been shown to be associated with DNA methylation changes \[[@CR47]--[@CR54]\]: age (years), sex (male/female), smoking status (current/former/never smoking), alcohol consumption (abstainer, low \[women, 0 to \< 20 g/d; men, 0 to \< 40 g/d\], intermediate \[20 to \< 40 g/d and 40 to \< 60 g/d, respectively\], high \[≥ 40 g/d and ≥ 60 g/d, respectively\]), body mass index (BMI, kg/m^2^, underweight \[\< 18.5, \< 1% of the study population\] or normal weight \[18.5 to \< 25\], overweight \[25 to \< 30\], obese \[≥ 30\]), physical activity (inactive \[\< 1 h of physical activity/week\], medium or high \[≥ 2 h of vigorous or ≥ 2 h of light physical activity/week\], low \[other\]), the leukocyte distribution estimated by the Houseman algorithm \[[@CR39]\], the prevalence of CVD (yes/no), diabetes (yes/no), and cancer (yes/no) at the baseline. After correction for multiple testing by false discovery rate (FDR, Benjamini-Hochberg method \[[@CR55]\]), SNP-CpG pairs with a FDR \< 0.05 were selected and then analyzed in the validation panel. SNPs of the pairs with a FDR \< 0.05 in the validation panel were eventually identified as the mQTL for the corresponding CpG site.

Furthermore, we tested the contributions of the identified mQTLs to the DNA methylation levels of corresponding CpG sites. Due to the limited number of individuals in the subgroup of minor homozygotes, we recoded the SNPs in order to use the dominant model, in which the heterozygote and minor homozygotes were combined as the carrier of minor allele and the major homozygotes were considered as non-carrier of the minor allele. We compared the coefficients of active smoking exposure (current vs. never smoking) in the fully adjusted model without the mQTLs (*β* ~1~) with the fully adjusted model including the mQTLs (*β* ~2~). The changes of coefficients were calculated as 100% \* (*β* ~1~--β~2~)/*β* ~1~, and their absolute values were determined as the percentage change contributed by mQTLs. The percentage changes were categorized by the absolute distances (bp) between CpG sites and corresponding mQTLs and the reported frequencies of CpG sites. To explore whether the gene-environment interactions could modify the DNA methylation changes of smoking-related CpG sites, we also tested whether interactions between the identified mQTLs and active smoking exposure (current vs. never smoking) could affect the impact of smoking on the methylation levels of corresponding CpG sites. The mQTLs, smoking status, and their interaction (mQTLs\*smoking status) were added in the model as predictors, and the methylation levels of CpG sites were outcomes. After controlling for all the potential covariates, the interactions with a FDR \< 0.05 were considered as methylation-related interactions for corresponding CpG sites.

Finally, we examined whether the identified mQTLs (carrier/non-carrier) were associated with six active smoking indicators: ever smoking (current and former smoking) vs. never smoking, current smoking vs. never smoking, current smoking vs. former smoking, cumulative smoking (pack-years), durations of smoking (years), and the age of smoking initiation. The mixed linear models were fully adjusted for age (years), sex, smoking status, alcohol consumption, BMI, physical activity, the prevalence of CVD, diabetes, and cancer as described above. The mQTLs with a FDR \< 0.05 were identified as smoking-related SNPs. We also assessed the associations of the significant mQTLs (carrier/non-carrier) with all-cause mortality in ESTHER study. Due to the limited number of deaths, we combined both subsets and performed the analysis using a multiple COX regression model. The model was adjusted for the above potential covariates and SNPs with a FDR \< 0.05 were considered as all-cause mortality related variants.

Data cleaning and all aforementioned statistical analyses were performed by SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). Manhattan plots for both panels were plotted by R package "ggplot2."
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Additional file 1: Table S1.Basic information of genomic data for 151 smoking-related CpG sites. **Table S2** List of 1396 significant SNP-CpG pairs in discovery panel. **Table S3** List of 246 significant SNP-CpG pairs in validation panel. **Table S4** Results of regression analyses for 246 SNP-CpG pairs in validation panel. **Table S5** Estimate changes of smoking status (never/current smoking) between models with and without adjusting for mQTLs. **Table S6** Impacts of mQTL-smoking interaction on the methylation levels of corresponding CpG sites in 949 participants (never/current smoking). **Table S7** Associations of 192 mQTLs with active smoking indicators. **Table S8.** Associations of 192 mQTLs with all-cause mortality. (XLSX 263 kb) Additional file 2: Figure S1.Manhattan plot of the results in discovery panel. (PDF 85 kb) Additional file 3: Figure S2.Locations and distributions of methylation levels of 19 smoking-related CpG sites based on the three most frequently identified mQTLs (carrier/non-carrier) and smoking status in validation panel. (PDF 206 kb)
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